ADAM 33 gene V4 C/G rs2787094 polymorphism in psoriasis

Akçılar, Raziye; Namdar, Nazlı Dizen; Koçak, Fatma Emel; Bayat, Zeynep; Burhan, Hakan

doi:10.4149/bll_2018_084

Cited by 2 publications

(2 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMP-1 [160], MMP-2 [45,157,160], MMP-3 [25], MMP-7 [109], MMP-8 [38], MMP-9 [5,14,45,157,160], MMP-12 [160,167], MMP-14 [45], MMP-15 [45], MMP-19 [166], MMP-26 [167], MMP-28 [196], ADAM-10 [109], ADAM-12 [109], ADAM-17 [75], ADAM-33 [3,198] • Adalimumab/Infliximab (anti-TNF-α Ab)…”

Section: Psoriasismentioning

confidence: 99%

Ab locks for improving the selectivity and safety of antibody drugs

Lin

Chuang

et al. 2020

J Biomed Sci

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are a major targeted therapy for malignancies, infectious diseases, autoimmune diseases, transplant rejection and chronic inflammatory diseases due to their antigen specificity and longer half-life than conventional drugs. However, long-term systemic antigen neutralization by mAbs may cause severe adverse events. Improving the selectivity of mAbs to distinguish target antigens at the disease site from normal healthy tissue and reducing severe adverse events caused by the mechanisms-of-action of mAbs is still a pressing need. Development of pro-antibodies (pro-Abs) by installing a protease-cleavable Ab lock is a novel and advanced recombinant Ab-based strategy that efficiently masks the antigen binding ability of mAbs in the normal state and selectively “turns on” the mAb activity when the pro-Ab reaches the proteolytic protease-overexpressed diseased tissue. In this review, we discuss the design and advantages/disadvantages of different Ab lock strategies, focusing particularly on spatial-hindrance-based and affinity peptide-based approaches. We expect that the development of different masking strategies for mAbs will benefit the local reactivity of mAbs at the disease site, increase the therapeutic efficacy and safety of long-term treatment with mAbs in chronic diseases and even permit scientists to develop Ab drugs for formerly undruggable targets and satisfy the unmet medical needs of mAb therapy.

show abstract

Section: Psoriasismentioning

confidence: 99%

Ab locks for improving the selectivity and safety of antibody drugs

Lin

Chuang

et al. 2020

J Biomed Sci

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a multifactorial relapsing and remitting infl ammatory skin disease. The prevalence of psoriasis ranged from 1.4 % to 3.3 % in Europe and North America (1)(2)(3). The disease (most often referred to as plaque psoriasis) represents about 4 % of all dermatoses which manifest at 16 years of age or younger (4,5).…”

Section: Psoriasismentioning

confidence: 99%

Variation of selected genotoxic and epigenetic markers due to therapeutic exposure to PAHs and ultraviolet radiation

Borský¹,

Chmelařová²,

Fiala³

et al. 2020

BLL

View full text Add to dashboard Cite

BACKGROUND: Goeckerman therapy (GT) of psoriasis involves dermal application of crude coal tar containing polycyclic aromatic hydrocarbons (PAHs) and exposure to ultraviolet radiation (UVR). Little is known about GT infl uence on DNA epigenetics. OBJECTIVE: The study aim was to discover epigenetic mechanisms altered by the exposure related to the GT of psoriasis. METHODS: Observed group of patients with plaque psoriasis (n = 23) was treated by GT with 3 % CCT. Before and after GT, we analyzed the levels of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts (BPDE-DNA), p53 protein in serum, 5-methylcytosine (5-mC, global DNA methylation), and methylation in selected CpG sites of p53 gene. RESULTS: We found a signifi cant increase in the levels of BPDE-DNA (p < 0.01) and serum levels of p53 protein (p < 0.01) after GT, and an insignifi cant decrease in the percentage of 5-mC in peripheral blood DNA. Methylation of p53 CpG sites was affected neither by psoriasis nor by GT. The study confi rmed good effectiveness of GT (signifi cantly reduced psoriasis area and severity index; p < 0.001). CONCLUSION: Our fi ndings indicate that there is a signifi cantly increased genotoxic hazard related to the exposure of PAHs and UV radiation after GT of psoriasis. However, global DNA methylation and p53 gene methylation evade the effect of GT, as they remained unchanged (Tab. 4, Fig. 3, Ref. 50).

show abstract

ADAM 33 gene V4 C/G rs2787094 polymorphism in psoriasis

Abstract: ADAM33 V4 C/G rs2787094 polymorphism was not associated with psoriasis risk in the Turkish population. Larger studies with different ethnicities are needed to determine the impact of ADAM33 polymorphism on the risk of developing psoriasis (Tab. 3, Fig. 1, Ref. 16).

Cited by 2 publications

References 17 publications

Ab locks for improving the selectivity and safety of antibody drugs

Ab locks for improving the selectivity and safety of antibody drugs

Variation of selected genotoxic and epigenetic markers due to therapeutic exposure to PAHs and ultraviolet radiation

Contact Info

Product

Resources

About